Novolog Flexpen

Drug: NovoLog FlexPen
Company: Novo Nordisk
Total spend Q1, 2012: $26.4 million
Total spend Q1, 2011: $1.4 million
Watch the TV commercial here >>

While not quite in the blockbuster category, the NovoLog FlexPen still raked in about $755 million in U.S. sales for Novo Nordisk ($NVO), according to drugs.com. And in the first quarter, it generated about $227 million, a 9% increase. The FlexPen, which allows users to dial in doses, and use short needles for injection, is a big step up from taking insulin with a hypodermic needle. Still the holy grail is oral insulin. And Novo Nordisk says it's willing to bet $2 billion in R&D that it can score a megablockbuster success in the field. Until then, its patent for the FlexPen is protected for a couple more years and the company says making a biosimilar of its product is no easy deal, so it may be safe for some time.

Novolog Flexpen
Read more on

Suggested Articles

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.